Gilteritinib + Venetoclax + Azacitidine (AZA) + Local standard of care (SOC)
Phase 2/3Recruiting 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
AML (Acute Myeloid Leukemia)
Conditions
AML (Acute Myeloid Leukemia)
Trial Timeline
Dec 1, 2026 → Feb 1, 2032
NCT ID
NCT07425808About Gilteritinib + Venetoclax + Azacitidine (AZA) + Local standard of care (SOC)
Gilteritinib + Venetoclax + Azacitidine (AZA) + Local standard of care (SOC) is a phase 2/3 stage product being developed by Astellas Pharma for AML (Acute Myeloid Leukemia). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07425808. Target conditions include AML (Acute Myeloid Leukemia).
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07425808 | Phase 2/3 | Recruiting |
Competing Products
6 competing products in AML (Acute Myeloid Leukemia)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ticagrelor 90 mg | AstraZeneca | Pre-clinical | 23 |
| Roflumilast + Placebo | AstraZeneca | Phase 2 | 52 |
| milatuzumab | Gilead Sciences | Phase 1 | 32 |
| Conditioning Regimen A + Conditioning Regimen B + Conditioning Regimen C + Conditioning Regimen D + Conditioning Regimen E + PTCy (50 mg/kg D3, D4) + PTCy (25 mg/kg D3, D4) + Post-transplant Tacrolimus + Post-transplant Mycophenolate mofetil + Post-transplant Abatacept + Post-transplant Ruxolitinib + Supportive Care: Growth Factors + Supportive Care: Seizure prophylaxis + Supportive Care: Prophylaxis against infections | Incyte | Phase 2 | 49 |
| Olutasidenib + CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates | Rigel Pharmaceuticals | Approved | 77 |
| p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine | Inovio Pharmaceuticals | Phase 2 | 44 |